EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Neoadjuvant Chemotherapy for Adults with Osteogenic Sarcoma

Michael J Robinson, Elizabeth J Davis

Current Treatment Options in Oncology · 2024-11 · 25 (11) · 1366-1373

DOI: 10.1007/s11864-024-01269-2 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Current Treatment Options in Oncology, online erschienen am 17.10.2024. Verfasst von Michael J Robinson und 1 weiteren Autor:innen. Beteiligte Einrichtung: Vanderbilt-Ingram Cancer Center, 2220 Pierce Ave, PRB 777, Nashville, TN, 37232, USA. Hauptthemen laut MEDLINE: Osteosarcoma, Neoadjuvant Therapy. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Opinion Statement Osteosarcoma is the most common primary malignant bone tumor in adolescents and adults. The 5-year survival rate is 65% when localized; however, survival drops dramatically to 10-20% in cases of metastatic disease. Therapy for osteosarcoma saw its first significant advancement in the 1970-80’s, with the introduction of our current standard of care, consisting of the neo/adjuvant treatment regimen methotrexate, doxorubicin (Adriamycin), and cisplatin (collectively referred to as MAP) and surgical resection. Since MAP, development of a better therapeutic approach has stalled, creating a plateau in patient outcomes that has persisted for 40 years. Despite substantial research into a variety of pathways for novel treatment options, clinical trials have not produced sizeable improvements in outcomes. In this article, we discuss our current neoadjuvant standard of care therapy, followed by a review of contemporary therapeutic options, including tyrosine kinase inhibitors (TKIs), immune checkpoint inhibitors (ICIs), monoclonal antibodies (mAbs), and chimeric antigen receptor (CAR) T cells. Lastly, we consider the challenges hindering the success of novel treatment options and future research directions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OsteosarcomaNeoadjuvant TherapyHumansAntineoplastic Combined Chemotherapy ProtocolsAdultBone NeoplasmsDisease ManagementTreatment OutcomeMolecular Targeted TherapyCombined Modality Therapy

Stichwörter der Autor:innen

Chimeric antigen receptor T cellsImmune Checkpoint InhibitorsImmunotherapyMonoclonal antibodiesOsteosarcomaReceptor tyrosine kinasesSystemic therapy

Autor:innen und Institutionen

  • Vanderbilt-Ingram Cancer Center, 2220 Pierce Ave, PRB 777, Nashville, TN, 37232, USA.
  • Vanderbilt-Ingram Cancer Center, 2220 Pierce Ave, PRB 777, Nashville, TN, 37232, USA. elizabeth.j.davis@vumc.org.

Zitieren

APA

Robinson, M. J., & Davis, E. J. (2024). Neoadjuvant Chemotherapy for Adults with Osteogenic Sarcoma. Current Treatment Options in Oncology, 25(11), 1366-1373. https://doi.org/10.1007/s11864-024-01269-2

Vancouver

Robinson MJ, Davis EJ. Neoadjuvant Chemotherapy for Adults with Osteogenic Sarcoma. Current Treatment Options in Oncology. 2024;25(11):1366-1373. doi:10.1007/s11864-024-01269-2

BibTeX
@article{Robinson2024,
  author = {Robinson, Michael J and Davis, Elizabeth J},
  title = {Neoadjuvant Chemotherapy for Adults with Osteogenic Sarcoma},
  journal = {Current Treatment Options in Oncology},
  year = {2024},
  volume = {25},
  number = {11},
  pages = {1366--1373},
  doi = {10.1007/s11864-024-01269-2}
}
Kostenlos starten →